Wednesday, March 2, 2011

New peptide could be effective treatment for triple negative breast cancer

New peptide could be effective treatment for triple negative breast cancer

Using a mouse model of triple negative breast cancer, they tested the new leptin receptor antagonist peptide and compared it to conventional chemotherapy. The leptin receptor antagonist peptide extended the average survival time by 80 percent, compared to 21 percent for chemotherapy. The peptide was found to be non-toxic even up to the highest dose administered, said Sumacz.